Research Specifications
- Molecule:
- BI 456906 — 29-amino-acid dual agonist peptide
- Developer:
- Boehringer Ingelheim / Zealand Pharma
- Class:
- GLP-1 / Glucagon dual agonist
- Vial:
- 10mg lyophilized
- Purity:
- ≥98% HPLC verified
Survodutide 10mg
GLP-1/Glucagon dual agonist (BI 456906)
CAS: 2230198-02-2
−18.7%
Weight loss (Ph2, 46 wk)
le Roux NEJM 2024
MASH
Second indication
Phase 3
Weekly
Dosing
Subcutaneous
Receptor Targets
Phase 3 for obesity (SYNCHRONIZE) and MASH
Developed by Boehringer Ingelheim / Zealand Pharma. Currently in active Phase 3 programs for both obesity and MASH as of 2024. No approvals yet.
Also Known As
Reconstitution & Dosing Guide
BAC Water
2mL
Final Concentration
5 mg/mL
Per Dose
2.4 mg = 0.48 mL · 4.8 mg (Phase 2 max) = 0.96 mL
Weekly subcutaneous dosing; titrate from 0.6 mg over 8–12 weeks
Often Stacked With
Published References
- 1.le Roux CW, Steen O, Lucas KJ, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity. New England Journal of Medicine (2024) PMID: 38767245
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| our verified supplier | >98% HPLC | $143.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Buy Peptides Compounds
Retatrutide 15mg
Retatrutide 20mg
Retatrutide 30mg
Semaglutide 12mg
Survodutide 10mg
$143.99